Exagen (XGN) Expected to Release Quarterly Earnings on Tuesday

Exagen (NASDAQ:XGN) is anticipated to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Exagen to announce earnings of ($0.19) per share and revenue of $17.80 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET.

Exagen (NASDAQ:XGN) last released its earnings results on Monday, May 11th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.07. The business had revenue of $17.31 million during the quarter, compared to analysts’ expectations of $16.41 million. Exagen had a negative net margin of 29.49% and a negative return on equity of 94.37%. On average, analysts expect Exagen to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Exagen Price Performance

Shares of XGN opened at $4.53 on Friday. The company has a market cap of $109.44 million, a price-to-earnings ratio of -5.09 and a beta of 2.02. Exagen has a 1-year low of $2.59 and a 1-year high of $12.23. The company’s fifty day simple moving average is $4.56 and its 200 day simple moving average is $3.85. The company has a current ratio of 3.47, a quick ratio of 3.47 and a debt-to-equity ratio of 1.67.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. BTIG Research cut their price target on shares of Exagen from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Canaccord Genuity Group lowered their price objective on shares of Exagen from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Roth Capital initiated coverage on shares of Exagen in a report on Wednesday, June 24th. They issued a “buy” rating and a $8.00 target price on the stock. Wall Street Zen upgraded shares of Exagen from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings cut Exagen from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Exagen currently has an average rating of “Moderate Buy” and an average price target of $9.00.

Hedge Funds Weigh In On Exagen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XGN. Balyasny Asset Management L.P. bought a new position in shares of Exagen in the second quarter valued at about $5,017,000. Invesco Ltd. bought a new stake in shares of Exagen during the 3rd quarter worth about $7,420,000. Mink Brook Asset Management LLC boosted its holdings in shares of Exagen by 784.3% during the 4th quarter. Mink Brook Asset Management LLC now owns 353,727 shares of the company’s stock worth $2,151,000 after buying an additional 313,727 shares during the period. Millennium Management LLC acquired a new position in Exagen in the 3rd quarter valued at about $2,716,000. Finally, Kennedy Capital Management LLC grew its stake in Exagen by 77.6% in the 3rd quarter. Kennedy Capital Management LLC now owns 551,848 shares of the company’s stock valued at $6,065,000 after buying an additional 241,127 shares during the last quarter. 75.25% of the stock is owned by institutional investors.

About Exagen

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.